Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02912455
Other study ID # 16-574
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 5, 2017
Est. completion date July 19, 2018

Study information

Verified date October 2020
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized clinical trial for patients with recurrent type 2 diabetes post-gastric bypass surgery that will compare a 6 month course of canagliflozin monotherapy vs. placebo on clinical outcomes of type 2 diabetes.


Description:

Following consent and a screening visit to assess eligibility and clinical status (i.e. historical, physical and biochemical parameters including glycemic control and a pregnancy test in females), a baseline visit with diabetes educator will take place to provide standard diabetes education, nutrition and exercise prescription. Nutritional assessment for vitamin/mineral deficiency will be performed per clinical care guidelines at the screening visit. Subjects will be asked to take nutritional supplements (i.e. vitamins and minerals) per current clinical guidelines for post-bariatric patients. Stable doses of supplements will be established for at least 2 weeks prior to randomization. Thirty-six subjects with recurrent diabetes that are naïve to hypoglycemic agents with HbA1c greater than or equal to 6.5% and less than 10% will be randomly assigned to a six month course of a) canagliflozin 100mg for 2 weeks titrated up to 300 mg daily (N = 24) vs. placebo (n= 12) at the randomization. Patients taking an anti-diabetic medication will be asked to wash out for 8 weeks prior to the randomization visit. At randomization, biochemical assessment of glycemic parameters (fasting glucose, HbA1c), lipid panel, complete metabolic panel, uric acid, leptin, total and HMW adiponectin, C-reactive protein and urine for albumin/creatinine ratio will be performed. Dual-energy x-ray absorptiometry (DXA) scan will be performed for body fat composition. Following randomization, subjects will be clinically evaluated at three office visits at 6 weeks, 3 and 6 months by PI and/or the research staff. The primary outcome measures at 6 months post-randomization include HbA1c followed by the change in HbA1c from randomization. Secondary measures include fasting glucose, BMI, change in body weight, blood pressure, lipid profile. Symptomatic hypoglycemia (blood glucose < 70) and drug related side effects (i.e. mycotic genital infections, urinary tract infection) will be monitored with adverse event reporting. Metabolic testing in all subjects at randomization and at 6 months will include a DXA scan for body fat composition and blood for leptin and adiponectin levels. Rescue glucose lowering therapy will be provided for the control group for blood glucose >250 mg/dl. If chronic uncontrolled hyperglycemia (HbA1c >10%) occurs then basal bolus insulin will be implemented.


Recruitment information / eligibility

Status Terminated
Enrollment 16
Est. completion date July 19, 2018
Est. primary completion date July 19, 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: - Post Roux-n-Y gastric bypass (RYGB) surgery and sleeve gastrectomy (SG) patients who underwent surgery >1 and <15 years ago in the Cleveland surrounding area - Age 20-75 years of age - Type II Diabetes Mellitus (D2M) diagnosis (history, medication usage, biochemical criteria) prior to and after surgery; after surgery, defined by a single HbA1c of greater or equal to 6.5% at consent and screening. - Metformin patients must have an HbA1c greater than or equal to 6.5% but less than or equal to 10% at randomization; for diet controlled patients (i.e. not on any T2D medication), HbA1c must be greater than or equal to 6.5% at randomization. - Patient reporting of improvement in T2D status or objective improvements in T2D status at any time post-surgery. - estimated glomerular filtration rate (eGFR) = 60mL/min prior to randomization - Has the ability and willingness to provide informed consent. - Is able to understand the options and to comply with the requirements of each program - Female subject agrees to have a serum pregnancy test at screening. A negative serum pregnancy test result is required prior to randomization. - Female patients must agree to use a reliable method of contraception for 6 months or duration of intervention - Patients taking an anti-diabetic medication, except insulin, are eligible and must agree to washout for 8 weeks prior to the randomization visit. Exclusion Criteria: - Type 1 diabetes indicated by history of diabetic ketoacidosis and lack of remission in response to bariatric surgery - Other post bariatric procedures (banding, duodenal switch, biliopancreatic diversion) - Current use of insulin. - End organ diabetic complications (renal failure, cardiomyopathy, severe neuropathy/foot ulcers) - Documented severe or unstable depression/anxiety or eating disorder that would not enable patient to adhere to anti-diabetic treatment - Clinical contraindications to use canagliflozin, i.e., history of bladder cancer, Child-Pugh class C

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
canagliflozin
encapsulated (gelatin capsule).
Placebo (for canagliflozin)
encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio

Sponsors (2)

Lead Sponsor Collaborator
The Cleveland Clinic Janssen Scientific Affairs, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change at Six Months Versus Baseline in Hemoglobin A1c Value (%) The change in hemoglobin A1c from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery 6 months
Secondary Change in Fasting Glucose From Randomization The change in fasting glucose from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery. 6 months
Secondary Change in Body Weight at Six Months Compared to Baseline The change in body weight from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery. 6 months
Secondary Change in Total Cholesterol The change in total cholesterol from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery 6 months
Secondary Change in Diastolic Blood Pressure at Six Months Compared to Baseline The change in diastolic blood pressure from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery 6 months
Secondary Change in Adiponectin Levels at 6 Months Compared to Randomization The change in adiponectin levels from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery. 6 months
Secondary Change in Leptin Levels at 6 Months Compared to Baseline Change in leptin levels at 6 months compared to baseline The change in leptin levels from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery. 6 months
Secondary Change in CRP Levels at 6 Months Compared to Baseline The change in C-reactive protein levels from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery. 6 months
Secondary Number of Participants Who Reported Hypoglycemia From Each Group (at a Frequency of 1 Episode) The number of participants who reported symptomatic hypoglycemia episodes from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery. 6 months
Secondary Change in Percent Body Fat as Measured by DEXA Scan at 6 Months Compared to Randomization The change in body fat from randomization following the 6 month administration of canagliflozin vs. placebo in patients with type 2 diabetes post-bariatric surgery. 6 months
Secondary Change in Systolic Blood Pressure at 6 Months Compared to Baseline The Change in Systolic Blood Pressure From Randomization Following the 6 Month Administration of Canagliflozin vs. Placebo in Patients With Type 2 Diabetes Post-bariatric Surgery 6 months
Secondary Change in Percentage of Lean Mass Change in percentage of lean body mass as measured by DEXA scan at 6 months compared to randomization 6 months
Secondary Change in Percentage of Truncal Fat Change in percentage of truncal fat as measured by DEXA scan at 6 months compared to randomization 6 months
Secondary Change in Percentage of Android Fat Change in percentage of android fat as measured by DEXA scan at 6 months compared to randomization 6 months
Secondary Change in Percentage of Gynoid Fat Change in percentage of gynoid fat as measured by DEXA scan at 6 months compared to randomization 6 months
Secondary Change in Spine Bone Mineral Density Change in spine bone marrow density as measured by DEXA scan at 6 months compared to randomization 6 months
Secondary Change in Leg Bone Mineral Density Change in leg bone marrow density as measured by DEXA scan at 6 months compared to randomization 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2